New weekly HIV pill matches daily treatment in landmark global trial Health Just now

“In the blinded, controlled conditions of a clinical trial, where both groups also took a matching placebo, so everyone was taking two sets of tablets, the weekly pill group was more adherent than the daily pill group,” says the study.

According to findings from the ISLEND-1 study, published in the New England Journal of Medicine on July 29, 2026, and presented the same week at the 26th International Aids Conference in Rio de Janeiro, the once-weekly pill kept the virus suppressed as effectively as the daily treatment.

After 48 weeks, the study met its primary goal of determining whether the once-weekly pill could suppress the virus as effectively as the daily regimen.